AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03021655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
Study NCT02370316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT-SA)
Description: MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
Study NCT04648202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS120
Description: Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
Study NCT02370316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Structured Treatment
Description: structured case management and symptom-targeted medication
Study NCT00943098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac HPBCD s.c. 75mg/ml
Description: 1 single injection at day of dental surgical extraction
Study NCT00943098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltarol 75mg/3ml i.m.
Description: 1 single injection at day of dental surgical extraction
Study NCT02066948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wt loss
Description: subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
Study NCT02547246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS session
Description: One session of rTMS at a frequency of 10 Hz during 20 minutes
Study NCT02547246 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS Placebo (SHAM)
Description: One session of placebo (SHAM) rTMS during 20 minutes
Study NCT01877525 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
Study NCT01081951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
Study NCT01081951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
Study NCT01081951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175mg/m2 iv for up to 6 cycles (18 weeks)
Study NCT00160251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
Study NCT00160251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
Study NCT02573298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ice
Description: local ice application for 30 minutes
Study NCT02573298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold gas
Description: local cold gas application for 2 minutes
Study NCT04069494 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Two questionnaires in patients and another two questionnaires in carer.
Study NCT01308671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
Study NCT01308671 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling and psychosocial support
Description: Blank group will receive the same counseling and psychosocial support as varenicline group
Study NCT01081951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: carboplatin
Description: AUC4 iv for up to 6 cycles (18 weeks)
Study NCT03733106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: digital breast tomosynthesis
Description: pseudo three dimension mammography
Study NCT03733106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard two dimension digital mammogram
Description: standard two dimension mammogram
Study NCT03261037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
Study NCT03261037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometry
Description: Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
Study NCT03261037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT
Description: The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
Study NCT03526692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
Study NCT00740818 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No Intervention
Description: The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
Study NCT00740818 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Logan Basic Adjustment
Description: A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
Study NCT00740818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic adjustment
Description: Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
Study NCT01860794 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesencephalic Neuronal Precursor Cells
Description: All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
Study NCT01468844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg pink opaque capsule
Study NCT01468844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01468844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study NCT01468844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study NCT02184390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On LIne Parent Training Tutorial
Description: Interactive on line tutorial for parenting skills for autism
Study NCT03944551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
Study NCT03944551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Therapy
Description: For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
Study NCT00758004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single dose of 80 mg atrovastatin tablet
Study NCT00758004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin pediatric appropriate formulation
Description: A single dose of pediatric appropriate atorvastatin 80 mg formulation
Study NCT04191694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
Study NCT04191694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
Study NCT04191694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron 4 MG
Description: Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
Study NCT03261739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYI-018
Description: Anti-CB1 monoclonal antibody
Study NCT00298623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 (GSK1838262)
Study NCT00298623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02675751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR S4 IR laser with iDesign
Description: Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
Study NCT02832557 — intervention group
Intervention type: OTHER
Intervention: Salivary collection
Description: Collection of saliva via swab for miRNA processing
Study NCT02832557 — intervention group
Intervention type: OTHER
Intervention: Vineland Adaptive Behavior Scale-III Assessment
Study NCT02832557 — intervention group
Intervention type: OTHER
Intervention: Medical history questionaire
Study NCT02832557 — intervention group
Intervention type: OTHER
Intervention: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)
Study NCT02832557 — intervention group
Intervention type: OTHER
Intervention: Mullen Scales of Early Learning
Study NCT00443053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux 2.5mg or placebo
Description: Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
Study NCT00443053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fondaparinux 2.5mg or placebo
Description: Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
Study NCT02620878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial pancreas
Description: Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
Study NCT02620878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump
Description: During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
Study NCT02441153 — intervention group
Intervention type: OTHER
Intervention: Extended Timing
Description: Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril, Sanofi Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril, Sanofi Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Bio-Manguinhos
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Bio-Manguinhos
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Institut Pasteur
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT02991495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Chumakov Institute
Description: 1. Full dose~2. Fractional dose: one fifth (1/5)
Study NCT00193791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT + RT
Description: Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
Study NCT04433637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cake + fruit juice
Description: Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
Study NCT04224714 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FFR
Description: FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
Study NCT03763656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hydroxyurea (100 mg/mL) Solution
Description: Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
Study NCT01191645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Description: Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
Study NCT01191645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
Study NCT01191645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
Study NCT01191645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
Study NCT01402557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Church Program
Description: An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
Study NCT01402557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Church Program
Description: An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
Study NCT01402557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Following completion of the weight loss program, participants will receive monthly telephone counseling.
Study NCT01402557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Following completion of the weight loss program, participants will receive monthly telephone counseling.
Study NCT01402557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Support
Description: After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
Study NCT01644669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative Radiation Therapy - IORT
Description: Single dose of 20 Gy
Study NCT02242214 — intervention group
Intervention type: DRUG
Intervention: Misoprostol
Study NCT01518686 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)
Description: We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)
Study NCT02358200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN-673
Study NCT02358200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02358200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01519687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levotofisopam
Description: 50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
Study NCT03654924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask
Description: General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
Study NCT03315793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Administered orally
Study NCT03315793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04120883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine lower dose
Description: The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
Study NCT04120883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine higher dose
Description: The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.